Amended Statement of Beneficial Ownership (3/a)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Young David

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/2/2020

3. Issuer Name and Ticker or Trading Symbol

Processa Pharmaceuticals, Inc. [PCSA]

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Executive Officer /

(Street)

HANOVER, MD 21076

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)
10/2/2020

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants (Right to Buy)	6/29/2018 ⁽¹⁾	6/29/2021	Common Stock	3147	$19.068	D
Warrants (Right to Buy)	6/29/2018 ⁽¹⁾	6/29/2021	Common Stock	20309	$19.068	I	By Family Entities
Warrants (Right to Buy)	6/29/2018 ⁽¹⁾	6/29/2021	Common Stock	15734	$19.068	I	By Young-Plaisance Revocable Trust
Warrants (Right to Buy)	5/25/2018 ⁽¹⁾	5/25/2021	Common Stock	14731	$17.164	I	By Young-Plaisance Revocable Trust

Explanation of Responses:
(1)	This amended Form 3 is being filed to add the grant date/exercise date of the warrant issued to the reporting person.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Young David C/O PROCESSA PHARMACEUTICALS, INC. 7300 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	X		Chief Executive Officer

Signatures
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact		10/5/2020
^**Signature of Reporting Person		Date

Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024

PCSA Processa Pharmaceuticals Inc